Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
November 15, 2024 09:38 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
November 07, 2024 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients
November 02, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
October 31, 2024 08:30 ET
|
Palisade Bio, Inc.
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects,...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
October 24, 2024 07:30 ET
|
Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
October 22, 2024 16:45 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq...
Funds urgently needed to support frontline heroes in a difficult world
October 15, 2024 10:55 ET
|
Primary Care Trauma Foundation
The Primary Care Trauma Foundation (PCTF) is a global charity that trains medics & lay volunteers to prepare for when the worst happens all over the world.
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
October 10, 2024 08:30 ET
|
Palisade Bio, Inc.
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
October 01, 2024 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung Cancer, Glioblastoma, Prostate Cancer, Melanoma, and Breast...
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
September 26, 2024 08:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment...